1. Dohner H, Fischer K, Bentz M, Hansen K, Benner A, Cabot G, Diehl D, Schluek R. Coy J, Stilgenbauer S, et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood. 1995; 85:1580-1589
2. Wattel E, Preudhomme C, Hecquet B, Vanrumbeke M, Quesnel B, Dervite I, Morel P, Fenaux P. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood. 1994; 84:3148-3157
3. el Rouby S, Thomas A, Costin D, Rosenberg C R, Potmesil M, Silber R, Newcomb E W. p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood. 1993; 82:3452-3459
4. Byrd J C, Smith L, Hackbarth M L, Flinn I W, Young D, Proffitt J H, Heerema N A. Interphase cytogenetic abnormalities in chronic lymphocytic leukemia may predict response to rituximab. Cancer Res. 2003; 63:36-38
5. Keating M J, Flinn I, Jain V, Binet J L, Hillmen P, Byrd J, Albitar M, Brettnall L, Santabarbara P, Wacker B, Rai K R. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood. 2002; 99:3554-3561
6. Stilgenbauer S, Dohner H. Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. N Engl J. Med. 2002; 347:452-453
7. Cheson B D, Bennett J M, Grever M, Kay N, Keating M J, O'Brien S, Rai K R. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996; 87:4990-4997
8. Rines R D, van Orsouw N J, Sigalas I, Li F P, Eng C, Vijg J. Comprehensive mutational scanning of the p53 coding region by two-dimensional gene scanning. Carcinogenesis. 1998; 19:979-984
9. Cordone I, Masi S, Mauro F R, Soddu S, Morsilli 0, Valentini T, Vegna M L, Guglielmi C, Mancini F, Giuliacci S, Sacchi A, Mandelli F, Foa R. p53 expression in B-cell chronic lymphocytic leukemia: a marker of disease progression and poor prognosis. Blood. 1998; 91:4342-4349
10. Sturm I, Bosanquet A G, Hermann S, Guner D, Dorken B, Daniel P T. Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapy. Cell Death Differ. 2003; 10:477-484
11. Silber R, Degar B, Costin D, Newcomb E W, Mani M, Rosenberg C R, Morse L, Drygas J C, Canellakis Z N, Potmesil M. Chemosensitivity of lymphocytes from patients with B-cell chronic lymphocytic leukemia to chlorambucil, fludarabine, and camptothecin analogs. Blood. 1994; 84:3440-3446
12. Pettitt A R, Sherrington P D, Stewart G, Cawley J C, Taylor A M, Stankovic T. p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation. Blood. 2001; 98:814-822
13. Pepper C, Thomas A, Hoy T, Tighe J, Culligan D, Fegan C, Bentley P. Leukemic and non-leukemic lymphocytes from patients with Li Fraumeni syndrome demonstrate loss of p53 function, Bcl-2 family dysregulation and intrinsic resistance to conventional chemotherapeutic drugs but not flavopiridol. Cell Cycle. 2003; 2:53-58